NA

Nucleic Acid Therapeutics

Nucleic Acid Therapeutics focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The journal examines new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for clinical purposes.

Looking to publish in Nucleic Acid Therapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Medicine, Research & Experimental
Impact Factor 4.7
Quartile Q2
Open Access Type Hybrid
ISSN 2159-3337
eISSN 2159-3345
Invitation Only No
Cost Range Title-specific APCs apply under Sage Choice pricing; some society-owned titles may also charge page or publication fees in addition to the Sage Choice fee.

Submission Instructions

Nucleic Acid Therapeutics accepts the following article types. Click on an article type to view submission instructions.

Original Paper

Cover Letter Any third-party writing or editing assistance and any non-author who submits on behalf of the authors must be disclosed in the covering letter.
Abstract Original Paper submissions must include an unstructured abstract. The abstract must not exceed 200 words. The abstract must be unstructured.
Manuscript Original Paper submissions have a 4,000-word limit. The main manuscript should generally include Abstract, Introduction, Methodology, Results, Discussion, Conclusion, Acknowledgments, Statements and Declarations, and References. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, a Statements and Declarations section with all required declaration headings including 'Not applicable' where relevant, and disclose AI use in the Acknowledgements or Methodology section when required.
References References must follow Sage Vancouver style. References must be numbered in the order cited, use superscript numerals in the text after punctuation, abbreviate journal titles according to Index Medicus, and list up to three authors before using et al. for additional authors.
Figures & Tables Original Paper submissions may include a maximum total of five figures and/or tables. Figures, charts, and tables created in Word should be included in the main text, while figures and other files created outside Word should be submitted separately with a placeholder note in the text. Figures and tables must be numbered consecutively, figures and tables must include a number and title, tables must be editable text rather than images, and raw data for figures must be provided.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Review Articles

Cover Letter A cover letter is required when third-party writing or editing assistance was used or when someone not listed as an author submitted on behalf of the authors. The cover letter must disclose any third-party writing or editing assistance and any submission made on behalf of the authors by a non-author.
Abstract An abstract is required. The abstract must be unstructured and no more than 200 words. The abstract must be unstructured.
Manuscript The manuscript must not exceed 10,000 words, excluding the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, and references. The main manuscript should generally include Abstract, Introduction, Methodology, Results, Discussion, Conclusion, Acknowledgments, Statements and Declarations, and References, with clear heading levels and clearly defined sections. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, a Statements and Declarations section with all required declaration headings including 'Not applicable' where relevant, and disclose AI use in the Acknowledgements or Methodology section when required.
References References must follow Sage Vancouver style. References must be numbered in the order cited, use abbreviated journal titles per Index Medicus, list up to three authors followed by et al. for additional authors, and use superscript numerals in the text after punctuation.
Figures & Tables Review Articles may include a maximum total of 10 figures and/or tables. Figures, charts, and tables created in Word should be included in the main text, while figures and other files created outside Word should be submitted separately with a placeholder note in the text. Tables must be editable text with a number and title, and all figures and tables must be numbered consecutively in the order they are cited.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Brief Communications

Cover Letter A cover letter is required only if third-party writing or editing assistance was used or if the submission was made by someone who is not an author. The cover letter must disclose any third-party writing or editing assistance and state if the submission was made on behalf of the authors by a non-author.
Abstract Brief Communications must include an abstract. The abstract must be unstructured and no more than 150 words. The abstract must be unstructured.
Manuscript The manuscript must not exceed 1,000 words, excluding the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, and references. Brief Communications may combine the Results and Discussion sections. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, and a Statements and Declarations section with all required declaration subheadings, using 'Not applicable' where a declaration does not apply.
References References must follow Sage Vancouver style. References must be numbered in the order cited, use abbreviated journal titles per Index Medicus, list up to three authors before using et al., and text citations must be superscript numerals placed after punctuation.
Figures & Tables Brief Communications may include a maximum of three figures and/or tables. Figures, charts, and tables created in Word should be embedded in the main text, while figures created outside Word should be uploaded separately with a placeholder in the text. Tables must be editable text with a number and title, and all figures and tables must be numbered consecutively in the order cited.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Letters To The Editor

Cover Letter Any third-party writing or editing assistance and any submission made by a non-author on behalf of the authors must be stated in the covering letter.
Abstract Abstract must not exceed 200 words. Abstract must be unstructured.
Manuscript Letters to the Editor must not exceed 500 words. Include at least 4 keywords after the abstract, an Author Contributions section after the Acknowledgements, and a Statements and Declarations section with all required declaration headings, using “Not applicable” where a declaration does not apply.
References Letters to the Editor may include a maximum of four references. References must follow Sage Vancouver style. References must be numbered in the order cited, use Index Medicus journal title abbreviations, list up to three authors before using et al., and text citations must be superscript numerals placed after punctuation.
Figures & Tables Letters to the Editor may include one figure or one table. Figures, charts, and tables created in Word should be included in the main text, while figures created outside Word should be submitted separately with a placeholder note in the text. Tables must be editable text with a number and title, and figures must be numbered consecutively and include a number and title.
Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Recent Publications

Exploring Clearance Pathways for GalNAc–siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications

Madeline C. Tompach, Kevin Craig, Shrutokirti De

10.1177/21593337261457402
View Publication

Reduced Genotoxicity Testing Is Possible for Noncoding Oligonucleotide-Based Therapeutics Containing Well-Characterized Modifications: A European Regulatory Perspective

Clara Stock, Britt Duijndam, Christine L.E. Siezen, Anna M.G. Pasmooij

10.1177/21593337261429852
View Publication

The Approval of Redemplo for Familial Chylomicronemia Syndrome and the Many Flavors of GalNAc-Oligonucleotides

Julia F. Alterman, Katherine Y. Gross, Anastasia Khvorova

10.1177/21593337261435980
View Publication

Efficient Downregulation of Flt-1 Mediated by Splice Switching ASO in Murine Endothelial Cells

Mathilde Blitek, Olivier Le Coz, Vincent Ogor, Hassan H. Fakih, Anastasia Khvorova, Aurélie Goyenvalle

10.1177/21593337261435971
View Publication

Rat and Rabbit Whole-Embryo Culture as a New Approach Method for Unlabeled Therapeutic Antisense Oligonucleotide Hazard Identification with No Requirement for Microinjection or Assisted Transfection

Sara M. Bender, Sharon Chapman, Sreenivas Nannapaneni, Joel D. Parry, Joyce Rendemonti, Stanley Robinson, Bradley Spencer-Dene, Dinesh Stanislaus

10.1177/21593337261442471
View Publication

Frequently asked questions

How long does it take to publish?

Peer review averages 25 days from submission to first decision, and online publication occurs within four weeks of acceptance.

Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Is a cover letter required?

A covering letter is required when third-party writing or editing assistance is received or when a submission is made on behalf of the authors by someone not listed as an author.

Reformat to Nucleic Acid Therapeutics using Livewrite Premium

What are the publication costs?

Title-specific APCs apply for Sage Choice hybrid open access after acceptance; some society-owned titles may also charge page or publication fees in addition to the APC.

Reformat to Nucleic Acid Therapeutics using Livewrite Premium

Research Topics

RNA Interference and Gene Delivery Advanced biosensing and bioanalysis techniques DNA and Nucleic Acid Chemistry RNA and protein synthesis mechanisms CRISPR and Genetic Engineering RNA Research and Splicing MicroRNA in disease regulation Virus-based gene therapy research Muscle Physiology and Disorders RNA modifications and cancer Neurogenetic and Muscular Disorders Research Immune Response and Inflammation RNA regulation and disease Immunotherapy and Immune Responses interferon and immune responses Genetic Neurodegenerative Diseases Bacteriophages and microbial interactions Monoclonal and Polyclonal Antibodies Research Viral Infections and Immunology Research Molecular Biology Techniques and Applications Immune Cell Function and Interaction Cancer-related molecular mechanisms research Blood Coagulation and Thrombosis Mechanisms Pluripotent Stem Cells Research Retinal Development and Disorders

Related Journals

Th
Theranostics Ivyspring International Publisher
CB
Cancer Biology and Medicine Chinese Anti-Cancer Association
CT
Cell Transplantation SAGE Publishing
TI
Trends in Molecular Medicine Elsevier BV
NV
npj Vaccines NATURE PORTFOLIO
Xe
Xenotransplantation WILEY